Search research articles
Contact Us
Filters
Showing results (611-620 of 704) with videos related to
Page
of 71
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 23, 2022
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
Jason A Chesney, Antoni Ribas, Georgina V Long, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 17, 2024
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial
Alexander Mm Eggermont, Michal Kicinski, Christian U Blank, et al.
Lancet (London, England)
|
June 4, 2015
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
Cancer Cell
|
December 24, 2021
Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance
Felicity Newell, Ines Pires da Silva, Peter A Johansson, et al.
The New England Journal of Medicine
|
September 12, 2017
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 4, 2019
Targeted Therapy in Advanced Melanoma With Rare <i>BRAF</i> Mutations
Christian Menzer, Alexander M Menzies, Matteo S Carlino, et al.
JAMA Oncology
|
January 3, 2020
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial
Alexander M M Eggermont, Michal Kicinski, Christian U Blank, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 22, 2021
Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma
Alexander Mm Eggermont, Andrey Meshcheryakov, Victoria Atkinson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 26, 2022
Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study
Leonie Müller-Jensen, Sarah Zierold, Judith M Versluis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 21, 2023
Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma
Selina K Wong, Steven M Blum, Xiaopeng Sun, et al.
Page
of 71
Search research articles
Search
Showing results (611-620 of 704) with videos related to
Sort By:
Page
of 71
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 23, 2022
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
Jason A Chesney, Antoni Ribas, Georgina V Long, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 17, 2024
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial
Alexander Mm Eggermont, Michal Kicinski, Christian U Blank, et al.
Lancet (London, England)
|
June 4, 2015
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
Cancer Cell
|
December 24, 2021
Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance
Felicity Newell, Ines Pires da Silva, Peter A Johansson, et al.
The New England Journal of Medicine
|
September 12, 2017
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 4, 2019
Targeted Therapy in Advanced Melanoma With Rare <i>BRAF</i> Mutations
Christian Menzer, Alexander M Menzies, Matteo S Carlino, et al.
JAMA Oncology
|
January 3, 2020
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial
Alexander M M Eggermont, Michal Kicinski, Christian U Blank, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 22, 2021
Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma
Alexander Mm Eggermont, Andrey Meshcheryakov, Victoria Atkinson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 26, 2022
Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study
Leonie Müller-Jensen, Sarah Zierold, Judith M Versluis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 21, 2023
Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma
Selina K Wong, Steven M Blum, Xiaopeng Sun, et al.
Page
of 71